Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab + Balstilimab vs Standard of Care in Advanced/Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT06346197Phase 3Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botensilimab and balstilimab in gastric cancer (GC), esophageal cancer and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Overall Survival. Started Dec 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06346197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346197.